Found: 7
Select item for more details and to access through your institution.
Academia and industry agreement on a feasibility tool for first‐time‐in‐human clinical trial units.
- Published in:
- CTS: Clinical & Translational Science, 2023, v. 16, n. 12, p. 2421, doi. 10.1111/cts.13655
- By:
- Publication type:
- Article
First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2024, v. 79, n. 6, p. 1353, doi. 10.1093/jac/dkae107
- By:
- Publication type:
- Article
Evening dosing is associated with higher plasma concentrations of pranlukast, a leukotriene receptor antagonist, in healthy male volunteers.
- Published in:
- British Journal of Clinical Pharmacology, 1997, v. 44, n. 3, p. 289, doi. 10.1046/j.1365-2125.1997.00650.x
- By:
- Publication type:
- Article
O3-04-06: Efficacy and tolerability of SB-742457, a novel 5HT<sub>6</sub> receptor antagonist, in subjects with mild-to-moderate Alzheimer's disease (AD)
- Published in:
- 2008
- By:
- Publication type:
- Abstract
Lack of Effect of Gemifloxacin on the Steady-State Pharmacokinetics of Theophylline in Healthy Volunteers.
- Published in:
- Chemotherapy (0009-3157), 1999, v. 45, n. 6, p. 478, doi. 10.1159/000007241
- By:
- Publication type:
- Article
Lack of Effect of Gemifloxacin on the Steady-State Pharmacodynamics of Warfarin in Healthy Volunteers.
- Published in:
- Chemotherapy (0009-3157), 1999, v. 45, n. 6, p. 491, doi. 10.1159/000007243
- By:
- Publication type:
- Article
Human Kinetic Modeling of the 5HT6 PET Radioligand <sup>11</sup>C-GSK215083 and Its Utility for Determining Occupancy at Both 5HT6 and 5HT2A Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease.
- Published in:
- Journal of Nuclear Medicine, 2015, v. 56, n. 12, p. 1901, doi. 10.2967/jnumed.115.162743
- By:
- Publication type:
- Article